Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578170 | 0.90 | USP2 (0.83) | KMT2AUSP2TSHRPKMLMNA | |
| SCHEMBL12834994 | 0.86 | USP2 (0.81) | KMT2AUSP2TSHRPKMMAPT | |
| SCHEMBL16370620 | 0.86 | L3MBTL1 (0.74) | KMT2AUSP2TSHRPKMMAPT | |
| SCHEMBL20437921 | 0.86 | KMT2A (0.94) | KMT2ATSHRMAPTLMNAALDH1A1 | |
| SCHEMBL20444278 | 0.84 | KMT2A (0.76) | KMT2AUSP2TSHRMAPTLMNA | |
| SCHEMBL16314566 | 0.83 | USP2 (0.73) | KMT2AUSP2TSHRPKMLMNA | |
| SCHEMBL10770632 | 0.83 | USP2 (0.73) | KMT2AUSP2TSHRPKMLMNA | |
| SCHEMBL20898158 | 0.83 | TSHR (0.97) | KMT2AUSP2TSHRPKMLMNA | |
| SCHEMBL24378058 | 0.83 | PKM (0.84) | KMT2AUSP2TSHRPKMALDH1A1 | |
| SCHEMBL8356145 | 0.83 | PKM (0.84) | KMT2AUSP2TSHRPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | KMT2A 333/4885USP2 3038/4885TSHR 3203/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | KMT2A 333/4885USP2 3038/4885TSHR 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.